Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04205227 · ClinicalTrials.gov registry record · Phase 1
ENB003 Plus Pembrolizumab Phase 1b/2a in Solid Tumors
A Phase 1 study of Cancer and Pancreatic Cancer, sponsored by ENB Therapeutics.
- Active
- Registry status
- Phase 1
- Development phase
- 137
- Enrollment target
- 5
- Study locations
NCT04205227 is a Phase 1 study of Cancer and Pancreatic Cancer that is active but no longer recruiting, run by ENB Therapeutics. The registered enrollment target is 137 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (96% lower). The trial reports 5 study locations across 3 states.
The verdict
NCT04205227, a Phase 1 study of Cancer and Pancreatic Cancer, is active but no longer recruiting, sponsored by ENB Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 137 participants
- Enrollment target
- 5
- Study locations
Study Summary
First-in Human study evaluating the safety, tolerability and efficacy of ENB003 in combination with Pembrolizumab in solid tumors. The study is separated into two parts. Part A is a 3+3 dose escalation to define the recommended RP2D; this part will include metastatic melanoma, platinum resistant ovarian cancer, and pancreatic cancer patients subjects, but other solid tumors will be allowed. Once the RP2D is selected, the study will be expanded into metastatic melanoma, platinum resistant ovarian cancer, and pancreatic cancer subjects. A small number of sarcoma subjects will be included, as exploratory.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG ENB003
Study Locations (5)
New South Wales
- Border Medical Oncology - Albury
- Blacktown Oncology - Blacktown
- Kinghorn-St Vincent's Hospital - Darlinghurst
California
- Cedars Sinai-The Angeles Clinic - Los Angeles
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 137 participants |
| Start Date | 2020-02-18 |
| Est. Completion | 2026-03-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04205227
The ClinicalTrials.gov registry entry for NCT04205227 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 137 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (96% lower). The listed sponsor is ENB Therapeutics, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Cancer appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT04205227 reports 5 study locations spanning 3 distinct geographic areas - top geographies include New South Wales, California, Texas.
Frequently Asked Questions
What is clinical trial NCT04205227 about?
NCT04205227 is a clinical study titled "ENB003 Plus Pembrolizumab Phase 1b/2a in Solid Tumors". First-in Human study evaluating the safety, tolerability and efficacy of ENB003 in combination with Pembrolizumab in solid tumors. The study is separated into two parts. Part A is a 3+3 dose escalation to define the recommended RP2D; this part will include metastatic melanoma, platinum resistant ova...
What is the current status of trial NCT04205227?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 137 participants. The study started on 2020-02-18. Estimated completion is 2026-03-31.
What conditions does trial NCT04205227 study?
This clinical trial studies the following conditions: Cancer, Pancreatic Cancer, Melanoma, Solid Tumor, Ovary Cancer.
What interventions are being tested in trial NCT04205227?
The interventions under investigation include: Pembrolizumab (DRUG), ENB003 (DRUG).
Who is sponsoring clinical trial NCT04205227?
This trial is sponsored by ENB Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04205227 being conducted?
This trial has 5 study locations across California, Texas, New South Wales. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
RECRUITING · Phase 1
-
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
RECRUITING · Phase 1
-
A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Impact of Daily Oral Cannabis Doses in Patients With Cancer
RECRUITING · Phase 1
-
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.